Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Yale University
Summary
This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.
Description
A randomized, double blind placebo controlled 20 week study of two doses of Semaglutide (SEMA) versus placebo in men and women with AUD and obesity (OB:BMI 30-49.9 kg/m2) will be studied to assess alcohol and food craving and stress in a validated laboratory model as well as examine changes in alcohol intake and related alcohol use outcomes during a 20 week clinical treatment and 8 week post-treatment follow-up phase of the study, in order to test mechanisms by which SEMA may exerts significant effects on alcohol use disorder outcomes.
Eligibility
- Age range
- 18–68 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male and females ages 18-60 and BMI in 30-49.9 kg/m2; * regular weekly alcohol use (at least 3X/week) prior to admission; * must meet current DSM-V criteria for moderate to severe Alcohol Use Disorders (AUDs) using SCID-I for DSM-V; * Good health as verified by screening and physical examination; * Able to read English and complete study evaluation; * Able to provide informed written and verbal consent. Exclusion Criteria: * Meet current criteria for moderate to severe substance use disorders from abuse of any another psychoactive substance, excluding nicotine; * Curre…
Interventions
- OtherPlacebo
Placebo - administered one weekly for 20 weeks
- DrugSemaglutide 1.0 mg
Semaglutide 1.0 mg low dose
- DrugSemaglutide 2.0 mg
Semaglutide 2.0 mg high dose
Location
- Yale Stress CenterNew Haven, Connecticut